Chong Kun Dang acquires U.S. process patent of CKD-11101, anemia therapy biosimilar

Chong Kun Dang(CEO Young-Joo Kim) announced on the 27^th that the company acquired a process patent of ‘CKD-11101,’ a second-generation biosimilar for the treatment of anemia, in the U.S.

The process patent, a patent for the new process method of darbepoetin alfa, the main substance of CKD-11101, is a differentiated manufacturing process which purify darbepoetin alfa that is difficult to be pur...